A head-to-head comparison of TNF-α inhibitors as the first biologic treatment of rheumatoid arthritis
This hypothesis-generating study provides evidence that TNFis may not be equally effective. The uncertainty in the estimates highlights the need for a pragmatic randomized controlled trial to validate the findings. With decreasing costs of TNFis, such studies are increasingly feasible and critical to guide clinical decision-making.
Authors
- K. M. Fagerli (ORCID: https://orcid.org/0000-0002-0327-7860)
- Eirik Klami Kristianslund (ORCID: https://orcid.org/0000-0002-4963-3285)
- Inge Christoffer Olsen (ORCID: https://orcid.org/0000-0001-6889-5873)
- Sella Aarrestad Provan (ORCID: https://orcid.org/0000-0001-5442-902X)
- Amir Aamodt Kazemi
- Joseph Sexton
Institutions
- Oslo University Hospital (NO)
- University of Oslo (NO)
- Diakonhjemmet Hospital (NO)
Publication Details
- Journal
- Lara D. Veeken
- Published
- 2026-01-14
- DOI
- https://doi.org/10.1093/rheumatology/keag007
- Primary Topic
- Rheumatoid Arthritis Research and Therapies
- Type
- article
- Field-Weighted Citation Impact
- 0.00